Shoji Ryosuke, Maeda Masayuki, Yamaguchi Kozue, Takuma Takahiro, On Rintaro, Ugajin Kazuhisa, Okatomi Daisuke, Fukuchi Kunihiko, Tokimatsu Issei, Ishino Keiko
Department of Infection Control Science, Showa Medical University Graduate School of Pharmacy, Shinagawa, Tokyo, Japan.
Department of Clinical Infectious Diseases, Showa Medical University Graduate School of Medicine, Shinagawa, Tokyo, Japan.
JAC Antimicrob Resist. 2025 Jun 3;7(3):dlaf097. doi: 10.1093/jacamr/dlaf097. eCollection 2025 Jun.
Studies combining linezolid resistance mechanisms and tedizolid susceptibility in linezolid-resistant clinical isolates are scarce. This study investigated the linezolid resistance mechanisms and tedizolid susceptibility of linezolid-resistant strains isolated clinically in Japan.
We analysed 25 linezolid-resistant strains of and isolated from Japanese hospitals between 2015 and 2021. MICs of linezolid and tedizolid were determined using the agar plate dilution method. Each 23S rRNA copy was amplified by PCR, sequenced and analysed for mutations. The linezolid resistance genes , , , and were also detected by PCR.
Drug susceptibility tests revealed that five linezolid-resistant isolates had low (≤1 mg/L) tedizolid MICs. Resistance mechanisms included the G2576T mutation in 23S rRNA, the T2504A mutation and the resistance genes , and . The T2504A mutation was identified in one isolate, which exhibited linezolid and tedizolid MICs of 64 and 32 mg/L, respectively.
Some linezolid-resistant isolates demonstrated low (≤1 mg/L) tedizolid MICs. To determine whether tedizolid susceptibility testing should be performed on linezolid-resistant isolates, more linezolid-resistant isolates should be collected and tested for tedizolid MICs. Tedizolid MICs were 2-3 doubling dilutions lower than linezolid MICs. The results of this study suggest that future research should investigate whether the T2504A mutation contributes to tedizolid resistance. To our knowledge, this is the first study to report tedizolid susceptibility in with the T2504A mutation and in isolate harbouring this mutation.
在耐利奈唑胺临床分离株中,将耐利奈唑胺机制与替加环素敏感性相结合的研究较少。本研究调查了在日本临床分离的耐利奈唑胺菌株的耐利奈唑胺机制及替加环素敏感性。
我们分析了2015年至2021年间从日本医院分离出的25株耐利奈唑胺的粪肠球菌和屎肠球菌。采用琼脂平板稀释法测定利奈唑胺和替加环素的最低抑菌浓度(MIC)。通过聚合酶链反应(PCR)扩增每个23S核糖体RNA(rRNA)拷贝,进行测序并分析突变情况。还通过PCR检测耐利奈唑胺基因cfr、cfr(C)、cfr(A)、cfr(B)和optrA。
药敏试验显示,5株耐利奈唑胺的肠球菌分离株具有较低(≤1mg/L)的替加环素MIC。耐药机制包括23S rRNA中的G2576T突变、T2504A突变以及耐药基因cfr、cfr(C)和optrA。在1株屎肠球菌分离株中鉴定出T2504A突变,其利奈唑胺和替加环素的MIC分别为64mg/L和32mg/L。
一些耐利奈唑胺分离株表现出较低(≤1mg/L)的替加环素MIC。为确定是否应对耐利奈唑胺分离株进行替加环素敏感性检测,应收集更多耐利奈唑胺分离株并检测其替加环素MIC。替加环素MIC比利奈唑胺MIC低2至3个稀释倍数。本研究结果表明,未来研究应调查T2504A突变是否导致替加环素耐药。据我们所知,这是第一项报告具有T2504A突变的屎肠球菌及携带该突变的分离株中替加环素敏感性的研究。